Skip to content

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Aug 2026

Discovery of Highly Potent and Selective, Orally Bioavailable BTK-Targeting PROTACs Featuring Novel CRBN-Binding Warheads.

Drugs targeting Bruton's tyrosine kinase (BTK) are recognized as key tools in hematological oncology. The clinical efficacy of BTK inhibitors is limited, however, by the emerging resistance driven by BTK mutations and the severe toxicity attributed to off-target kinase inhibition. PROteolysis TArgeting Chimeras (PROTAC...

A. Mantsyzov, Pei Zhao, Chris Kruse et al. · 0 citations
Open access Sep 2026

Integration of proteomic aging clocks in a phase 2a clinical trial supports simultaneous geroprotective assessment.

This work supports the goal of dual-purpose clinical trial designs that integrate aging endpoints into studies for specific disease indications by identifying potential anti-aging shifts in senescence and metabolic processes alongside the anti-fibrotic activity of rentosertib.

Alex Zhavoronkov, F. Galkin, Shan Chen et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.